

The Microbiome and Pancreatic Cancer

Subjects: Oncology

Contributor: Sona Ciernikova

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignant tumors due to the absence of biomarkers for early-stage detection and poor response to therapy.

Keywords: pancreatic ductal adenocarcinoma ; dysbiosis ; pancreatic microbiome ; tumor microenvironment

1. Oral and Gut Microbiome in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent neoplastic disease of the pancreas accounting for more than 90% of all pancreatic malignancies [1]. It is the fourth most frequent cause of cancer-related deaths worldwide and is projected to be the second cause of cancer-related deaths by 2030 [2]. Genetic susceptibility, age, gender, ethnicity, diabetes mellitus, as well as alcohol abuse, vitamin D deficiency, tobacco use, high body mass index, and lack of physical activity tend to increase the development of PDAC [3]. Additionally, pancreatic inflammation is considered a long-term risk factor, and chronic pancreatitis supposed to raise the risk for PDAC up to 20 times [4]. Maekawa et al. observed that *Enterococcus faecalis* or lipoteichoic acid might aggravate pancreatic inflammation by stimulating inflammatory cytokines [5].

The composition of the oral, gut, and pancreatic microbiome in PDAC patients showed diverse alterations compared to healthy individuals. Prior studies support the existence of complex interactions between various host microbiomes and the pancreas. This communication shapes immune regulation influences the gastrointestinal microbiota via antimicrobial peptides derived from the pancreas and modulates the effect of PDAC therapy (Figure 1).




Figure 1. The pancreatic microbiota as a component of the tumor microenvironment. Disruption of gut microbiota leads to enhanced bacterial translocation and subsequent activation of TLRs signaling pathway in the pancreatic environment. Besides, decreased SCFA metabolites negatively influence the production of pancreatic antimicrobial peptides. Microbiota-derived signals might affect pancreatic oncogenesis via NF-κB/MAPK, STAT3, or mTOR tumor-related inflammatory pathways. Moreover, immune response modulation leading to reduced Th1 CD4⁺ and CD8⁺ T cell differentiation and increased Th2 levels as well as the production of pro-tumorigenic metabolites might represent the pro-oncogenic mechanisms. Since microbiota has been recognized as an important part of the PDAC microenvironment, possible interactions with PSCs/CAFs need to be considered and further evaluated. Importantly, microbiota-dependent remodeling of tumor microenvironment towards PDAC immunosuppression has been reported, suggesting the complex interplay between all components within the tumor might affect the sensitivity to PDAC treatment. Abbreviations: CAFs, cancer-associated fibroblasts; MAPK, a mitogen-activated protein kinase; MDSCs, myeloid-derived suppressor cells;

mTOR, the mammalian target of rapamycin; NF- κ B, nuclear factor kappa-light-chain-enhancer of activated B cells; PAMPs, pathogen-associated molecular patterns; PDAC, pancreatic ductal adenocarcinoma; PSCs, pancreatic stellate cells; SCFA, short-chain fatty acid; STAT3, signal transducer and activator of transcription 3; Th2 cells, T helper 2 cells; T reg cells, regulatory T cells; TLRs, Toll-like receptors

Oral health status with regard to inflammation of the gingiva [6][7], periodontal disease [8], and tooth loss [9] represent independent risk factors for PDAC. The exact mechanisms by which oral microbiota reach the pancreas are still unknown, but the proposed mechanisms involve the translocation via biliary/pancreatic ducts or through the blood circulation [10]. Variations in salivary microbiota from patients with pancreatitis and PDAC support the possibility of using salivary microbial biomarkers for systemic diseases prediction [11]. Interestingly, the associations between oral pathogens *Porphyromonas gingivalis*, *Fusobacterium*, *Neisseria elongata*, and *Streptococcus mitis*, and PDAC tumorigenesis have been evaluated. In this context, *P. gingivalis* showed a strong positive correlation with PDAC susceptibility. A detailed meta-analysis of 49 case-control studies comprising 5924 individuals (patients with periodontal disease and healthy controls) found a strong correlation between the presence of *P. gingivalis* and periodontal diseases [12]. Importantly, *P. gingivalis* was associated with an increased risk of PDAC with 59% greater risk of PDAC in a cohort of 361 PDAC patients compared to 371 matched-healthy controls [13]. Moreover, *Fusobacterium* spp. have been detected in pancreatic cancer tissue and show significant association with a worse prognosis [14].

Data from murine models demonstrated that the gut microbiome can colonize pancreatic tumors and modify its overall intratumoral bacterial composition. *Helicobacter pylori* became an established risk factor for gastric cancer and its role in PDAC development has also been assessed. One of the first observations came from the analysis of IgG antibodies against *H. pylori* by enzyme-linked immunosorbent assays. High seropositivity was detected in blood samples from patients with pancreatic and gastric cancer (65% and 69%, respectively) compared to other individuals [15]. A prospective study on more than 50,000 male participants revealed an increased risk of pancreatic tumors related to gastric ulcer. As the authors acknowledged, the elevated risk might be associated with greater endogenous nitrosamine formation and inflammatory response due to *H. pylori* infection [16]. Some studies and meta-analyses confirmed the link between *H. pylori* and increased risk of PDAC [17][18], while others did not support these findings [19]. Very recently, Hirabayashi et al. performed a large population-based cohort study in a Japanese population showing *H. pylori* infection and atrophic gastritis (AG) were not generally associated with the risk of pancreatic cancer; however, a significant positive correlation was detected among current smokers with AG [20]. Due to the conflicting results, further research is warranted to determine the true impact of *H. pylori* in pancreatic carcinogenesis.

2. Pancreatic Tumor Micro- and Mycobiome

The microbiome analysis of patients undergoing pancreaticoduodenectomy revealed distinct bacterial populations in fluids collected from the bile duct, pancreas, and jejunum [21]. Gaiser et al. observed significantly higher intracystic bacterial 16S DNA copy number and IL-1 β quantification in intraductal papillary mucinous neoplasms (IPMN) with high-grade dysplasia and IPMN with cancer compared to non-IPMN neoplasms. Additionally, co-occurrence and enrichment of oral bacterial taxa including *Fusobacterium nucleatum* and *Granulicatella adiacens* was found in cyst fluid from IPMN with high-grade dysplasia [22]. Detection of bacterial 16S ribosomal DNA by qPCR in tumor samples from 113 PDAC patients revealed bacterial DNA in 86/113 (76%) PDAC samples compared to 3/20 (15%) in normal pancreas controls obtained from organ donors ($p < 0.005$). Fluorescence in situ hybridization (FISH) with fluorescent 16S rRNA-targeted probes, and immunohistochemistry, using an antibacterial lipopolysaccharide (LPS) antibody confirmed the intratumoral localization of bacteria in a PDAC cohort [23]. Recently, Nejman et al. performed the most comprehensive analysis of the tumor microbiome to date, showing a distinct composition of intratumoral microbiota relating to seven cancer types. As shown, the microbiome from pancreatic carcinomas had copied the main signature of the normal duodenal microbial composition with dominance of Proteobacteria phylum. Moreover, breast and pancreatic tumor samples were found to be enriched by *Fusobacterium nucleatum* [24].

A comparison of fecal microbiota from PDAC patients and healthy controls showed a higher abundance of Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia in the gut of cancer patients. Interestingly, Proteobacteria (45%), Bacteroidetes (31%), and Firmicutes (22%) were most abundant within the intratumoral microbiome of PDAC patients [25]. This finding confirmed the previous results by Geller et al. considering the possible mechanism of interaction between the two compartments by a retrograde bacterial translocation from the duodenum via pancreatic ducts [23]. Metagenomic analysis of 68 tumor samples from PDAC patients showed the correlation between pancreatic tumor microbiome and patients' survival. Microbial comparison of two cohorts identified as short-term survivors (STS) and long-term survivors (LTS) showed that tumors of LTS were characterized by a significantly higher alpha diversity ($p < 0.05$ for each alpha diversity index), and infiltration with cytotoxic CD8/killer T cells compared to STS. Importantly, both cohorts were age,

gender, stage, and treatment matched. According to the findings, tumor bacterial diversity was associated with OS (median survivals of the patients with high versus low alpha diversity were 9.66 and 1.66 years, respectively). This finding correlates with results showing that low bacterial diversity is linked to a worse outcome for cancer patients, especially those with hematologic malignancies. The ability of the gut microbiome to modulate the pancreatic tumor microbiome and influence tumor growth was confirmed by animal models with FMT from pancreatic STS, LTS, and healthy donors. Moreover, the positive effect of FMT on intratumoral immune cell infiltration has been observed [26].

However, not only the gut microbiome but also the gut mycobiome can directly influence the pancreatic microenvironment. Oral gavage of control and pancreatic-tumor bearing mice with GFP-labeled *Saccharomyces cerevisiae* indicated that endoluminal fungi could access the pancreas. According to the findings, both mouse and human PDAC tumors exhibited a greater than 3000-fold increase in the abundance of fungi compared with normal pancreas. Furthermore, a distinct composition of mycobiome and enrichment with *Malassezia* spp. has been observed in adenocarcinoma samples. The ablation experiments confirmed the accelerated oncogenesis after *Malassezia globosa* repopulation in murine models, suggesting the participation of the C3 complement cascade via mannose-binding lectin activation in promoting PDAC [27].

The application of individual microbial signatures as the early biomarkers for cancer development and prognostic indicators of treatment response is still an important challenge for microbiota research in PDAC patients. Moreover, the existence of communication between the gut and pancreatic cancer-specific microbiome brings new opportunities for the studies related to the therapeutical implication of microbiota modulation.

References

1. Kleeff, J.; Korc, M.; Apte, M.; La Vecchia, C.; Johnson, C.D.; Biankin, A.V.; Neale, R.E.; Tempero, M.; Tuveson, D.A.; Hruban, R.H.; et al. Pancreatic cancer. *Nat. Rev. Dis. Primers* **2016**, *2*, 16022, [10.1038/nrdp.2016.22](https://doi.org/10.1038/nrdp.2016.22).
2. Rahib, L.; Smith, B.D.; Aizenberg, R.; Rosenzweig, A.B.; Fleshman, J.M.; Matrisian, L.M.; Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res.* **2014**, *74*, 2913–2921, [10.1158/0008-5472](https://doi.org/10.1158/0008-5472).
3. Rawla, P.; Sunkara, T.; Gaduputi, V.; Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. *World J. Oncol* **2019**, *10*, 10–27, [10.14740/wjon1166](https://doi.org/10.14740/wjon1166).
4. Lowenfels, A.B.; Maisonneuve, P.; Cavallini, G.; Ammann, R.W.; Lankisch, P.G.; Andersen, J.R.; Dimagno, E.P.; Andr n-Sandberg, A.; Domell f, L.; Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. *N. Engl. J. Med.* **1993**, *328*, 1433–1437, [10.1093/jnci/89.6.442](https://doi.org/10.1093/jnci/89.6.442).
5. Maekawa, T.; Fukaya, R.; Takamatsu, S.; Itoyama, S.; Fukuoka, T.; Yamada, M.; Hata, T.; Nagaoka, S.; Kawamoto, K.; Eguchi, H.; et al. Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer. *Biochem. Biophys. Res. Commun* **2018**, *506*, 962–969, [10.1016/j.bbrc.2018.10.169](https://doi.org/10.1016/j.bbrc.2018.10.169).
6. Bracci, P.M. Cancer J. 2017, 23, 310–314; Oral Health and the Oral Microbiome in Pancreatic Cancer: An Overview of Epidemiological Studies. *Cancer J.* **2017**, *23*, 310–314, [10.1097/PPO.0000000000000287](https://doi.org/10.1097/PPO.0000000000000287).
7. Heikkil , P.; But, A.; Sorsa, T.; Haukka, J.; Periodontitis and cancer mortality: Register-based cohort study of 68,273 adults in 10-year follow-up. *Int. J. Cancer* **2018**, *142*, 2244–2253, [10.1002/ijc.31254](https://doi.org/10.1002/ijc.31254).
8. Michaud, D.S.; Joshupura, K.; Giovannucci, E.; Fuchs, C.S.; prospective study of periodontal disease and pancreatic cancer in US male health professionals. *J. Natl. Cancer Inst.* **2007**, *99*, 171–175, [10.1093/jnci/djk021](https://doi.org/10.1093/jnci/djk021).
9. Meyer, M.S.; Joshupura, K.; Giovannucci, E.; Michaud, D.S.; A review of the relationship between tooth loss, periodontal disease, and cancer. *Cancer Causes Control* **2008**, *9*, 550–558, [10.1016/S1470-2045\(08\)70106-2](https://doi.org/10.1016/S1470-2045(08)70106-2).
10. Fritz, S.; Hackert, T.; Hartwig, W.; Rossmann, F.; Strobel, O.; Schneider, L.; Will-Schweiger, K.; Kommerell, M.; B chler, M.W.; Werner, J.; et al. Bacterial translocation and infected pancreatic necrosis in acute necrotizing pancreatitis derives from small bowel rather than from colon. *Am. J. Surg.* **2010**, *200*, 111–117, [10.1016/j.amjsurg.2009.08.019](https://doi.org/10.1016/j.amjsurg.2009.08.019).
11. Farrell, J.J.; Zhang, L.; Zhou, H.; Chia, D.; Elashoff, D.; Akin, D.; Paster, B.J.; Joshupura, K.; Wong, D.T.; Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. *Gut* **2012**, *61*, 582–588, [10.1136/gutjnl-2011-300784](https://doi.org/10.1136/gutjnl-2011-300784).
12. Rafiei, M.; Kiani, F.; Sayehmiri, F.; Sayehmiri, K.; Sheikhi, A.; Zamanian Azodi, M.; study of Porphyromonas gingivalis in periodontal diseases: A systematic review and meta-analysis. *Med. J. Islam. Repub. Iran* **2017**, *31*, 62, [10.18869/mjiri.31.62](https://doi.org/10.18869/mjiri.31.62).
13. Fan, X.; Alekseyenko, A.V.; Wu, J.; Peters, B.A.; Jacobs, E.J.; Gapstur, S.M.; Purdue, M.P.; Abnet, C.C.; Stolzenberg-Solomon, R.; Miller, G.; et al. Human oral microbiome and prospective risk for pancreatic cancer: A population-based

nested case-control study. *Gut* **2018**, 67, 120–127, [10.1136/gutjnl-2016-312580](https://doi.org/10.1136/gutjnl-2016-312580).

14. Mitsuhashi, K.; Nosho, K.; Sukawa, Y.; Matsunaga, Y.; Ito, M.; Kurihara, H.; Kanno, S.; Igarashi, H.; Naito, T.; Adachi, Y.; et al. Association of *Fusobacterium* species in pancreatic cancer tissues with molecular features and prognosis. *Oncotarget* **2015**, 6, 7209–7220, [10.18632/oncotarget.3109](https://doi.org/10.18632/oncotarget.3109).
15. Raderer, M.; Wrba, F.; Kornek, G.; Maca, T.; Koller, D.Y.; Weinlaender, G.; Hejna, M.; Scheithauer, W.; Association between *Helicobacter pylori* infection and pancreatic cancer. *Oncology* **1998**, 55, 16-19, [10.1159/000011830](https://doi.org/10.1159/000011830).
16. Bao, Y.; Spiegelman, D.; Li, R.; Giovannucci, E.; Fuchs, C.S.; Michaud, D.S.; History of peptic ulcer disease and pancreatic cancer risk in men. *Gastroenterology* **2010**, 138, 541–549, [10.1053/j.gastro.2009.09.059](https://doi.org/10.1053/j.gastro.2009.09.059).
17. Guo, Y.; Liu, W.; Wu, J.; *Helicobacter pylori* infection and pancreatic cancer risk: A meta-analysis. *J. Cancer Res. Ther.* **2016**, 12, C229–C232, [10.4103/0973-1482.200744](https://doi.org/10.4103/0973-1482.200744).
18. Schulte, A.; Pandeya, N.; Fawcett, J.; Fritschi, L.; Risch, H.A.; Webb, P.M.; Whiteman, D.C.; Neale, R.E.; Association between *Helicobacter pylori* and pancreatic cancer risk: A meta-analysis. *Cancer Causes Control* **2015**, 26, 1027–1035, [10.1007/s10552-015-0595-3](https://doi.org/10.1007/s10552-015-0595-3).
19. Wang, Y.; Zhang, F.C.; Wang, Y.J.; *Helicobacter pylori* and pancreatic cancer risk: A meta- analysis based on 2,049 cases and 2,861 controls. *Asian Pac. J. Cancer Prev.* **2014**, 15, 4449–4454, [10.7314/apjcp.2014.15.11.4449](https://doi.org/10.7314/apjcp.2014.15.11.4449).
20. Hirabayashi, M.; Inoue, M.; Sawada, N.; Saito, E.; Abe, S.K.; Hidaka, A.; Iwasaki, M.; Yamaji, T.; Shimazu, T.; Tsugane, S.; et al. *Helicobacter pylori* infection, atrophic gastritis, and risk of pancreatic cancer: A population-based cohort study in a large Japanese population: The JPHC Study. *Sci. Rep.* **2019**, 9, 6099, [10.1038/s41598-019-42365-w](https://doi.org/10.1038/s41598-019-42365-w).
21. Rogers, M.B.; Aveson, V.; Firek, B.; Yeh, A.; Brooks, B.; Brower-Sinning, R.; Steve, J.; Banfield, J.F.; Zureikat, A.; Hogg, M.; et al. Disturbances of the Perioperative Microbiome Across Multiple Body Sites in Patients Undergoing Pancreaticoduodenectomy. *Pancreas* **2017**, 46, 260-267, [10.1097/MPA.0000000000000726](https://doi.org/10.1097/MPA.0000000000000726).
22. Gaiser, R.A.; Halimi, A.; Alkharaan, H.; Lu, L.; Davanian, H.; Healy, K.; Hugerth, L.W.; Atee, Z.; Valente, R.; Fernández Moro, C.; et al. Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer. *Gut* **2019**, 68, 2186–2194, [10.1136/gutjnl-2018-317458](https://doi.org/10.1136/gutjnl-2018-317458).
23. Geller, L.T.; Barzily-Rokni, M.; Danino, T.; Jonas, O.H.; Shental, N.; Nejman, D.; Gavert, N.; Zwang, Y.; Cooper, Z.A.; Shee, K.; et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. *Science* **2017**, 357, 1156–1160, [10.1126/science.aah5043](https://doi.org/10.1126/science.aah5043).
24. Nejman, D.; Livyatan, I.; Fuks, G.; Gavert, N.; Zwang, Y.; Geller, L.T.; Rotter-Maskowitz, A.; Weiser, R.; Mallel, G.; Gigi, E.; et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. *Science* **2020**, 368, 973–980, [10.1126/science.aay9189](https://doi.org/10.1126/science.aay9189).
25. Pushalkar, S.; Hundeyin, M.; Daley, D.; Zambirinis, C.P.; Kurz, E.; Mishra, A.; Mohan, N.; Aykut, B.; Usyk, M.; Torres, L.E.; et al. The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. *Cancer Discov.* **2018**, 8, 403–416, [10.1126/science.aay9189](https://doi.org/10.1126/science.aay9189).
26. Riquelme, E.; Zhang, Y.; Zhang, L.; Montiel, M.; Zoltan, M.; Dong, W.; Quesada, P.; Sahin, I.; Chandra, V.; San Lucas, A.; et al. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. *Cell* **2019**, 178, 795–806.e712, [10.1016/j.cell.2019.07.008](https://doi.org/10.1016/j.cell.2019.07.008).
27. Aykut, B.; Pushalkar, S.; Chen, R.; Li, Q.; Abengozar, R.; Kim, J.I.; Shadaloey, S.A.; Wu, D.; Preiss, P.; Verma, N.; et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. *Nature* **2019**, 574, 264–267, [10.1038/s41586-019-1608-2](https://doi.org/10.1038/s41586-019-1608-2).